The potential nephrotoxic effect of single tablet of 15 mg primaquine in G6PD deficient Hadoti region population of India
| Autor: | Yogesh Kumar Swami, Umashankar Nama, Pavankumar Pyarsabadi, Saurabh Chittora, Hemant Richariya, Vikash Khandelia |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Primaquine Population Plasmodium vivax Renal function 01 natural sciences Nephrotoxicity 03 medical and health sciences Internal medicine medicine In patient education Intensive care medicine education.field_of_study biology business.industry Acute kidney injury biology.organism_classification Haemolysis medicine.disease 0104 chemical sciences 010404 medicinal & biomolecular chemistry 030104 developmental biology business medicine.drug |
| Zdroj: | International Journal of Advances in Medicine. 4:605 |
| ISSN: | 2349-3933 2349-3925 |
| DOI: | 10.18203/2349-3933.ijam20170899 |
| Popis: | Primaquine is used in prevention of relapse of plasmodium vivax and ovale. It is known to cause haemolysis induced acute kidney injury in patients with glucose-6-phosphate dehydrogenase (G-6-PD) enzyme deficiency. Primaquine is widely used in the remote areas of Hadoti region of India by many non-registered practitioners for treatment of febrile illnesses without prior testing of G-6-PD status. Due to this practice, many patients land up with the grave consequences with significant health care burden. We report 8 such cases, which were referred to our hospital, New hospital medical college, Kota, Rajasthan, India. Our study included a series of 8 cases which were referred to our hospital with significantly deranged renal function test due to use of primaquine without prior testing of G-6-PD status. Routine blood investigations including renal function tests and G-6-PD status were measured. In our study, we found that patients with febrile illness and G-6-PD deficiency developed acute kidney injury even with a single tablet of 15 mg of primaquine. The use of even a single dose of 15 mg primaquine may not be safe in population of Hadoti region of India. Hence they should not be exposed to primaquine without prior G-6-PD testing. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|